Thurston Springer Miller Herd & Titak Inc. Has $108,000 Position in Becton, Dickinson and Company $BDX

Thurston Springer Miller Herd & Titak Inc. cut its position in Becton, Dickinson and Company (NYSE:BDX) by 92.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 578 shares of the medical instruments supplier’s stock after selling 6,649 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Becton, Dickinson and Company were worth $108,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Aptus Capital Advisors LLC raised its position in shares of Becton, Dickinson and Company by 6.8% during the first quarter. Aptus Capital Advisors LLC now owns 14,651 shares of the medical instruments supplier’s stock worth $3,356,000 after purchasing an additional 927 shares during the period. Hsbc Holdings PLC lifted its holdings in shares of Becton, Dickinson and Company by 0.6% during the 1st quarter. Hsbc Holdings PLC now owns 661,269 shares of the medical instruments supplier’s stock valued at $151,189,000 after purchasing an additional 4,155 shares in the last quarter. Legacy Financial Advisors Inc. grew its position in shares of Becton, Dickinson and Company by 19.2% in the 1st quarter. Legacy Financial Advisors Inc. now owns 1,132 shares of the medical instruments supplier’s stock valued at $259,000 after purchasing an additional 182 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S increased its stake in Becton, Dickinson and Company by 96.7% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 33,694 shares of the medical instruments supplier’s stock worth $7,718,000 after purchasing an additional 16,568 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 629 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the transaction, the executive vice president directly owned 13,105 shares of the company’s stock, valued at approximately $2,568,973.15. This trade represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 1,036 shares of company stock valued at $197,225. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research note on Wednesday. Finally, Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Four investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $205.64.

Becton, Dickinson and Company Stock Down 0.5%

Shares of BDX stock opened at $195.46 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The firm’s fifty day moving average price is $189.18 and its two-hundred day moving average price is $185.09. The firm has a market capitalization of $55.79 billion, a P/E ratio of 33.53, a PEG ratio of 1.81 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.